Clinical Trials for Advanced Solid Tumors: Immunotherapy, Targeted Agents, and Platinum Chemotherapy
This community focuses on the clinical evaluation of treatment regimens for advanced solid tumors, specifically testing the efficacy and safety of immunotherapies, targeted drugs, and platinum-based chemotherapy in patients with lung, ovarian, bladder, and head and neck cancers.
The research is dominated by phase III clinical trials assessing combination therapies. Recurring treatments include immune checkpoint inhibitors (such as pembrolizumab and nivolumab), antibody-drug conjugates, and targeted agents like osimertinib, often administered alongside or in place of platinum-based chemotherapy (cisplatin or carboplatin). The primary cancer types studied are non-small cell lung cancer, epithelial ovarian cancer, urothelial (bladder) carcinoma, and squamous cell carcinoma of the head and neck. The literature frequently addresses locally advanced or metastatic disease, with a strong emphasis on neoadjuvant settings and the management of platinum-resistant or recurrent cases.
Platinum research accounts for the largest share of this community's output, representing 11.3% of all tracked platinum research and comprising 18,211 papers within this group. This element leads on both the proportion of its total research and the raw paper count within the community.
The community comprises 47,837 papers, with the highest publication volume in the Journal of Clinical Oncology, Frontiers in Oncology, and Cancers.
Recent work continues to focus on perioperative immunotherapy for bladder and lung cancer, the use of antibody-drug conjugates in EGFR-mutated non-small cell lung cancer, and updated treatment guidelines for gastric and ovarian malignancies.